PI3K inhibitors in inflammation, autoimmunity and cancer.
Hessel, Edith M
Curr Opin Pharmacol
MetadataShow full item record
Stark, A., Sriskantharajah, S., Hessel, E. M., & Okkenhaug, K. (2015). PI3K inhibitors in inflammation, autoimmunity and cancer.. Curr Opin Pharmacol, 23 82-91. https://doi.org/10.1016/j.coph.2015.05.017
The healthy immune system protects against infection and malignant transformation without causing significant damage to host tissues. Immune dysregulation results in diverse pathologies including autoimmune disease, chronic inflammatory disorders, allergies as well as immune deficiencies and cancer. Phosphoinositide 3-kinase (PI3K) signalling has been shown to be a key pathway in the regulation of the immune response and continues to be the focus of intense research. In recent years we have gained detailed understanding of PI3K signalling, and saw the development of potent and highly selective small molecule inhibitors, of which several are currently in clinical trials for the treatment of immune-related disorders and cancer. The role of PI3K signalling in the immune response has been the subject of detailed reviews; here we focus on relevant recent progress in pre-clinical and clinical development of PI3K inhibitors.
Animals, Humans, Neoplasms, Autoimmune Diseases, Inflammation, Enzyme Inhibitors, Autoimmunity, Clinical Trials as Topic, Phosphatidylinositol 3-Kinases, Phosphoinositide-3 Kinase Inhibitors
Embargo Lift Date
External DOI: https://doi.org/10.1016/j.coph.2015.05.017
This record's URL: https://www.repository.cam.ac.uk/handle/1810/277594
Attribution 4.0 International
Licence URL: http://creativecommons.org/licenses/by/4.0/
Recommended or similar items
The following licence files are associated with this item: